Abstract | BACKGROUND: METHODS:
Chemotherapy-naive elderly patients with SCLC received amrubicin (35 mg/m(2), days 1-3) and carboplatin [area under the curve (AUC) 4.0, day1] every 3 weeks. The primary end point was overall response rate (ORR), and secondary end points were progression-free survival (PFS), overall survival and toxicity profile. RESULTS: From January 2005 to November 2007, 36 patients were enrolled [median age 76 (range 70-83); ECOG performance status of zero and one in 17 and 19 patients, respectively]. One complete response and 31 partial responses were observed (ORR 89%). Median PFS was 5.8 months and median survival time was 18.6 months. Grade 3-4 neutropenia was observed in 97% of the patients and six patients (17%) suffered from grade 3-4 febrile neutropenia. Other toxic effects were moderate and treatment-related death was not observed. CONCLUSIONS:
Amrubicin combined with carboplatin is quite effective for SCLC with acceptable toxic effects even for the elderly population. Further evaluation of this regimen is warranted.
|
Authors | A Inoue, O Ishimoto, S Fukumoto, K Usui, T Suzuki, H Yokouchi, M Maemondo, M Kanbe, S Ogura, T Harada, S Oizumi, M Harada, S Sugawara, T Fukuhara, T Nukiwa |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 21
Issue 4
Pg. 800-803
(Apr 2010)
ISSN: 1569-8041 [Electronic] England |
PMID | 19825887
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Anthracyclines
- amrubicin
- Carboplatin
|
Topics |
- Aged
- Aged, 80 and over
- Anthracyclines
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Female
- Humans
- Japan
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Small Cell Lung Carcinoma
(drug therapy, mortality)
- Societies, Medical
- Survival Analysis
- Treatment Outcome
|